La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Herbalife a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Herbalife..

Herbalife (NYSE:HLF) Azioni, Catena delle Opzioni

Herbalife

Herbalife Nutrition

Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.

Scopri le tre azioni su cui gli insider stanno investendo massicciamente e le motivazioni dietro questi acquisti strategici.

Le 3 azioni su cui gli insider scommettono forte: ecco perché

Herbalife Ltd

HONG LEONG BANK BHD by Hong Leong Bank BHD

HONG LEONG FINCL GRP ORD by Hong Leong Financial Group BHD

Hong Leong Financial Group Bhd

HALFORDS GROUP PLC ORD by Halfords Group Plc

Halfords Group PLC

HALFORDS GROUP UNSP/ADR by Halfords Group Plc

HelloFresh SE

HILTON FOOD GROUP ADR by HILTON FOOD GROUP PLC

Hilton Food Group PLC

HOME LOAN FINCL CORP by Home Loan Financial Corp.

Home Loan Financial Corp

Mizuho analyst John Baumgartner maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and raises the price target from $8 to $9.

News

Price Target

Analyst Ratings

Mizuho Maintains Neutral on Herbalife, Raises Price Target to $9

New daily supplement features clinically studied botanicals to support weight loss, healthy fat reduction and energy expenditure&#x2A;
Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>), a premier health and wellness company, community and platform, today announced the launch of MultiBurn&#x2122; — a next-generation multi-action dietary supplement designed with clinically studied botanical extracts to support key areas of metabolic health&#x2A;. Formulated by Herbalife's global team of scientists and nutrition experts, MultiBurn&#x2122; is gluten-free, suitable for vegans and made without synthetic colors or dyes, reflecting the company's commitment to clean-label, user-friendly wellness solutions.

Herbalife Unveils MultiBurn, Next-Gen Multi-Action Dietary Supplement, To Support Weight Loss, Healthy Fat Reduction And Energy Expenditure

Certified Method Enhances Global Botanical Quality and Safety

Herbalife's Aloe Vera Aloin Testing Method Earns AOAC INTERNATIONAL Certification

Earnings

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Herbalife to report an earnings per share (EPS) of $0.41.
The market awaits Herbalife's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.14 in the last quarter, leading to a 42.7% increase in the share price on the following day.
Here's a look at Herbalife's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.41</td>
<td>0.22</td>
<td>0.35</td>
<td>0.41</td>
<td>0.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.59</td>
<td>0.36</td>
<td>0.57</td>
<td>0.54</td>
<td>0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>43.0%</td>
<td>11.0%</td>
<td>-9.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058577_0.png" alt="eps graph" />
<h3>Tracking Herbalife's Stock Performance</h3>
Shares of Herbalife were trading at $6.73 as of May 09. Over the last 52-week period, shares are down 36.34%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HLF/earnings">To track all earnings releases for Herbalife visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Herbalife's Earnings Forecast

Citigroup analyst Chasen Bender maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Buy and lowers the price target from $13 to $11.

Citigroup Maintains Buy on Herbalife, Lowers Price Target to $11

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) narrows FY2025 sales outlook from $4.84 billion-$5.14 billion to $4.87 billion-$5.12 billion vs $4.96 billion estimate.

Guidance

Herbalife Narrows FY2025 Sales Guidance from $4.84B-$5.14B to $4.87B-$5.12B vs $4.96B Est

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) sees Q2 sales of $1.236 billion-$1.288 billion vs $1.27 billion analyst estimate.

Herbalife Sees Q2 Sales $1.236B-$1.288B vs $1.27B Est

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.37 by 59.46 percent. This is a 20.41 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.22 billion which missed the analyst consensus estimate of $1.23 billion by 0.26 percent. This is a 3.32 percent decrease over sales of $1.26 billion the same period last year.

Earnings Beats

Earnings Misses

Herbalife Q1 Adj. EPS $0.59 Beats $0.37 Estimate, Sales $1.22B Miss $1.23B Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Herbalife will report an earnings per share (EPS) of $0.40.
Herbalife bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.14, leading to a 42.7% increase in the share price the following trading session.
Here's a look at Herbalife's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.22</td>
<td>0.35</td>
<td>0.41</td>
<td>0.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.36</td>
<td>0.57</td>
<td>0.54</td>
<td>0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>43.0%</td>
<td>11.0%</td>
<td>-9.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745949730_0.png" alt="eps graph" />
<h3>Tracking Herbalife's Stock Performance</h3>
Shares of Herbalife were trading at $6.9 as of April 28. Over the last 52-week period, shares are down 20.22%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/HLF/earnings">To track all earnings releases for Herbalife visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: Herbalife's Earnings Outlook

WIIM

COTY

FRPT

LFVN

LOCL

MGRX

PFGC

USFD

Shares of companies within the broader consumer staples sector are trading lower as stocks pull back after surging Wednesday following President Trump's tariff pause announcement.

DA Davidson analyst Linda Bolton Weiser upgrades Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) from Neutral to Buy and raises the price target from $7.5 to $14.

Upgrades

DA Davidson Upgrades Herbalife to Buy, Raises Price Target to $14

Herbalife Announces Acquisition Of Pro2col, Pruvit, And 51% Stake in Link BioSciences, Terms Not Disclosed

Comments

Herbalife

Herbalife (HLF) Opzioni

Loading...

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO